Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
86.74 EUR | -2.04% | -4.69% | -3.34% |
Jun. 11 | Transcript : Sanofi Presents at Goldman Sachs 45th Annual Global Healthcare Conference, Jun-11-2024 02:00 PM | |
Jun. 11 | CAC40: declines below 7800 points, weighed down by banks | CF |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
Strengths
- Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
- The company returns high margins, thereby supporting business profitability.
- The company is in a robust financial situation considering its net cash and margin position.
- This company will be of major interest to investors in search of a high dividend stock.
- Analysts covering this company mostly recommend stock overweighting or purchase.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
- The opinion of analysts covering the stock has improved over the past four months.
- Consensus analysts have strongly revised their opinion of the company over the past 12 months.
Weaknesses
- For the past year, analysts have significantly revised downwards their profit estimates.
- For the last few months, analysts have been revising downwards their earnings forecast.
Ratings chart - Surperformance
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-3.34% | 116B | - | ||
+41.96% | 630B | B | ||
-7.15% | 350B | C+ | ||
+18.77% | 328B | B- | ||
+8.79% | 298B | C+ | ||
+18.02% | 246B | B+ | ||
+1.27% | 225B | A+ | ||
+11.95% | 218B | B- | ||
+3.68% | 160B | C+ | ||
-4.38% | 156B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- SAN Stock
- SNW Stock
- Ratings Sanofi